15. Как не умереть от ятрогенных причин

‹‹1››. Pereira TV, Horwitz RI, Ioannidis JPA. Empirical evaluation of very large treatment effects of medical interventions. JAMA. 2012;308(16):1676–84.

‹‹2››. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.

‹‹3››. Starfield B. Is US health really the best in the world? JAMA. 2000;284(4):483–5.

‹‹4››. Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122(2):160–6.

‹‹5››. Gilbert K, Stafford C, Crosby K, Fleming E, Gaynes R. Does hand hygiene compliance among health care workers change when patients are in contact precaution rooms in ICUs? Am J Infect Control. 2010;38(7):515–7.

‹‹6››. Gilbert K, Staff ord C, Crosby K, Fleming E, Gaynes R. Does hand hygiene compliance among health care workers change when patients are in contact precaution rooms in ICUs? Am J Infect Control. 2010;38(7):515–7.

‹‹7››. Leape LL, Berwick DM. Five years after To Err Is Human: what have we learned? JAMA. 2005;293(19):2384–90.

‹‹8››. Starfield B. Is US health really the best in the world? JAMA. 2000;284(4):483–5.

‹‹9››. Institute of Medicine. To Err Is Human: building a safer health system. http://www.iom.edu/~/media/Files/Report%20Files/1999/To-Err-is-Human/To%20Err%20is%20Human%201999%20%20report%20brief.pdf. November, 1999. Accessed March 12, 2015.

‹‹10››. Weingart SN, Wilson RM, Gibberd RW, Harrison B. Epidemiology of medical error. BMJ. 2000;320(7237):774–7.

‹‹11››. Millenson ML. The silence. Health Aff (Millwood). 2003;22(2):103–12.

‹‹12››. Mills DH. Medical insurance feasibility study. A technical summary. West J Med. 1978; 128(4): 360–5.

‹‹13››. Leape LL. Error in medicine. JAMA. 1994 Dec 21;272(23):1851–7.

‹‹14››. Millenson ML. The silence. Health Aff (Millwood). 2003;22(2):103–12.

‹‹15››. Institute of Medicine. To Err Is Human: building a safer health system. http://www.iom.edu/~/media/Files/Report%20Files/1999/To-Err-is-Human/To%20Err%20is%20Human201999%20%20report%20brief.pdf. November, 1999. Accessed March 12, 2015.

‹‹16››. Millenson ML. The silence. Health Aff (Millwood). 2003;22(2):103–12.

‹‹17››. Lockley SW, Barger LK, Ayas NT, Rothschild JM, Czeisler CA, Landrigan CP. Effects of health care provider work hours and sleep deprivation on safety and performance. Jt Comm J Qual Patient Saf. 2007;33(11 Suppl):7–18.

‹‹18››. Barger LK, Ayas NT, Cade BE, et al. Impact of extended-duration shifts on medical errors, adverse events, and attentional failures. PLoS Med. 2006;3(12):e487.

‹‹19››. Millenson ML. The silence. Health Aff (Millwood). 2003;22(2):103–12.

‹‹20››. Egger GJ, Binns AF, Rossner SR. The emergence of «lifestyle medicine» as a structured approach for management of chronic disease. Med J Aust. 2009;190(3):143–5.

‹‹21››. Malone J, Guleria R, Craven C, et al. Justification of diagnostic medical exposures: some practical issues. Report of an International Atomic Energy Agency Consultation. Br J Radiol. 2012;85(1013):523–38.

‹‹22››. Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, part I. Cancer: 1950–1990. 1996. Radiat Res. 2012;178(2): AV61–87.

‹‹23››. Brenner D, Elliston C, Hall E, Berdon WE. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289–96.

‹‹24››. Rogers LF. Taking care of children: check out the parameters used for helical CT. AJR Am J Roentgenol. 2001;176(2):287.

‹‹25››. Berrington de Gonzingt A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22): 2071–7.

‹‹26››. Institute of Medicine. Breast cancer and the environment: a life course approach. Washington, D.C.: The National Academies Press; 2012.

‹‹27››. Picano E. Informed consent and communication of risk from radiological and nuclear medicine examinations: how to escape from a communication inferno. BMJ. 2004;329(7470):849–51.

‹‹28››. Schmidt CW. CT scans: balancing health risks and medical benefits. Environ Health Perspect. 2012;120(3):A118–21.

‹‹29››. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499–505.

‹‹30››. Limaye MR, Severance H. Pandora’s boxes: questions unleashed in airport scanner debate. J Am Osteopath Assoc. 2011;111(2):87–8, 119.

‹‹31››. Friedberg W, Copeland K, Duke FE, O’Brien K, Darden EB. Radiation exposure during air travel: guidance provided by the Federal Aviation Administration for air carrier crews. Health Phys. 2000;79(5):591–5.

‹‹32››. Yong LC, Petersen MR, Sigurdson AJ, Sampson LA, Ward EM. High dietary antioxidant intakes are associated with decreased chromosome translocation frequency in airline pilots. Am J Clin Nutr. 2009;90(5):1402–10.

‹‹33››. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature. 1998;392(6676):559.

‹‹34››. Yong LC, Petersen MR, Sigurdson AJ, Sampson LA, Ward EM. High dietary antioxidant intakes are associated with decreased chromosome translocation frequency in airline pilots. Am J Clin Nutr. 2009;90(5):1402–10.

‹‹35››. Yong LC, Petersen MR, Sigurdson AJ, Sampson LA, Ward EM. High dietary antioxidant intakes are associated with decreased chromosome translocation frequency in airline pilots. Am J Clin Nutr. 2009;90(5):1402–10.

‹‹36››. Sauvaget C, Kasagi F, Waldren CA. Dietary factors and cancer mortality among atomic-bomb survivors. Mutat Res. 2004;551(1–2):145–52.

‹‹37››. Kordysh EA, Emerit I, Goldsmith JR, et al. Dietary and clastogenic factors in children who immigrated to Israel from regions contaminated by the Chernobyl accident. Arch Environ Health. 2001;56(4):320–6.

‹‹38››. Langham WH, Bassett H, Harris PS, Carter RE. Distribution and excretion of plutonium administered intravenously to man. Los Alamos: Los Alamos Scientific Laboratory, LAB1151. Health Physics. 1980;38:1,031B1,060.

‹‹39››. Loscialpo MJ. Nontherapeutic human research experiments on institutionalized mentally retarded children: civil rights and remedies. 23 New Eng J on Crim & Civ Confinement. 1997;139: 143–5.

‹‹40››. Assistant to the Secretary of Defense for Nuclear and Chemical and Biological Defense Programs, Department of Defense. Report on search for human radiation experiment records 1944–1994. http://www.defense.gov/pubs/dodhre/. June 1997. Accessed March 12, 2015.

‹‹41››. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broadspectrum radioprotector. Oncologist. 2007;12(6):738–47.

‹‹42››. Rao BN, Archana PR, Aithal BK, Rao BSS. Protective Effect of zingerone, a dietary compound against radiation induced genetic damage and apoptosis in human lymphocytes. Eur J Pharmacol. 2011;657(1–3):59–66.

‹‹43››. Arora R, Gupta D, Chawla R, et al. Radioprotection by plant products: present status and future prospects. Phytother Res. 2005;19(1):1–22.

‹‹44››. Malekirad AA, Ranjbar A, Rahzani K, et al. Oxidative stress in radiology staff.Environ Toxicol Pharmacol. 2005;20(1):215–8.

‹‹45››. Zeraatpishe A, Oryan S, Bagheri MH, et al. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicol Ind Health. 2011;27(3):205–12.

‹‹46››. Zhong W, Maradit-Kremers H, St Sauver JL, et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc. 2013;88(7):697–707.

‹‹47››. Lindsley CW. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci. 2012;3(8):630–1.

‹‹48››. Centers for Disease Control National Center for Health Statistics. National Ambulatory Medical Care Survey: 2010 Summary Tables. http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2010_namcs_web_tables.pdf. 2010. Accessed March 12, 2015.

‹‹49››. Hudson B, Zarifeh A, Young L, Wells JE. Patients’ expectations of screening and preventive treatments. Ann Fam Med. 2012;10(6):495–502.

‹‹50››. Lytsy P, Westerling R. Patient expectations on lipid-lowering drugs. Patient Educ Couns. 2007;67(1–2):143–50.

‹‹51››. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients’ expectation of benefi t from preventive drugs. Clin Med. 2002;2(6):527–33.

‹‹52››. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients’ expectation of benefi t from preventive drugs. Clin Med. 2002;2(6):527–33.

‹‹53››. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients’ expectation of benefi t from preventive drugs. Clin Med. 2002;2(6):527–33.

‹‹54››. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients’ expectation of benefi t from preventive drugs. Clin Med. 2002;2(6):527–33.

‹‹55››. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014;63(7):356–364b.

‹‹56››. Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014;63(7):356–364b.

‹‹57››. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. Food Funct. 2011;2(9):515–20.

‹‹58››. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123(7):768–78.

‹‹59››. Pasche B, Wang M, Pennison M, Jimenez H. Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol. 2014;41(3):397–401.

‹‹60››. Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget. 2012;3(8):893–906.

‹‹61››. Macdonald S. Aspirin use to be banned in under 16 year olds. BMJ. 2002;325(7371):988.

‹‹62››. Siller-Matula JM. Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? JAMA. 2012;307(21):2318–20.

‹‹63››. Sutcliffe P, Connock M, Gurung T, et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS ONE. 2013;8(12):e81970.

‹‹64››. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259–67.

‹‹65››. McCarty MF. Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. Med Hypotheses. 2012;78(1):45–57.

‹‹66››. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. Food Funct. 2011;2(9):515–20.

‹‹67››. Paterson JR, Blacklock C, Campbell G, Wiles D, Lawrence JR. The identifi cation of salicylates as normal constituents of serum: a link between diet and health? J Clin Pathol. 1998;51(7): 502–5.

‹‹68››. Rinelli S, Spadafranca A, Fiorillo G, Cocucci M, Bertoli S, Battezzati A. Circulating salicylic acid and metabolic and inflammatory responses after fruit ingestion. Plant Foods Hum Nutr. 2012;67(1):100–4.

‹‹69››. Blacklock CJ, Lawrence JR, Wiles D, et al. Salicylic acid in the serum of subjects not taking aspirin. Comparison of salicylic acid concentrations in the serum of vegetarians, non-vegetarians, and patients taking low dose aspirin. J Clin Pathol. 2001;54(7):553–5.

‹‹70››. Knutsen SF. Lifestyle and the use of health ser vices. Am J Clin Nutr. 1994;59(5 Suppl):1171S–1175S.

‹‹71››. McCarty MF. Dietary nitrate and reductive polyphenols may potentiate the vascular benefit and alleviate the ulcerative risk of low-dose aspirin. Med Hypotheses. 2013;80(2):186–90.

‹‹72››. Willcox BJ, Willcox DC, Todoriki H, et al. Caloric restriction, the traditional Okinawan diet, and healthy aging: the diet of the world’s longest-lived people and its potential impact on morbidity and life span. Ann N Y Acad Sci. 2007;1114:434–55.

‹‹73››. McCarty MF. Minimizing the cancer-promotional activity of cox-2 as a central strategy in cancer prevention. Med Hypotheses. 2012;78(1):45–57.

‹‹74››. Paterson JR, Srivastava R, Baxter GJ, Graham AB, Lawrence JR. Salicylic acid content of spices and its implications. J Agric Food Chem. 2006;54(8):2891–6.

‹‹75››. Paterson JR, Srivastava R, Baxter GJ, Graham AB, Lawrence JR. Salicylic acid content of spices and its implications. J Agric Food Chem. 2006;54(8):2891–6.

‹‹76››. Pasche B, Wang M, Pennison M, Jimenez H. Prevention and treatment of cancer with aspirin: where do we stand? Semin Oncol. 2014;41(3):397–401.

‹‹77››. Paterson JR, Srivastava R, Baxter GJ, Graham AB, Lawrence JR. Salicylic acid content of spices and its implications. J Agric Food Chem. 2006;54(8):2891–6.

‹‹78››. Baxter GJ, Graham AB, Lawrence JR, Wiles D, Paterson JR. Salicylic acid in soups prepared from organically and non-organically grown vegetables. Eur J Nutr. 2001;40(6):289–92.

‹‹79››. Scheier L. Salicylic acid: one more reason to eat your fruits and vegetables. J Am Diet Assoc. 2001;101(12):1406–8.

‹‹80››. Duthie GG, Wood AD. Natural salicylates: foods, functions and disease prevention. Food Funct. 2011;2(9):515–20.

‹‹81››. Seeff LC, Richards TB, Shapiro JA, et al. How many endoscopies are performed for colorectal cancer screening? Results from CDC’s survey of endoscopic capacity. Gastroenterology. 2004;127(6):1670–7.

‹‹82››. McLachlan SA, Clements A, Austoker J. Patients’ experiences and reported barriers to colonoscopy in the screening context— a systematic review of the literature. Patient Educ Couns. 2012;86(2):137–46.

‹‹83››. Lobel EZ, Korelitz BI. Postendoscopy syndrome: «the doctor never talked to me.» J Clin Gastroenterol. 2001;33(5):353–4.

‹‹84››. McLachlan SA, Clements A, Austoker J. Patients’ experiences and reported barriers to colonoscopy in the screening context— a systematic review of the literature. Patient Educ Couns. 2012;86(2):137–46.

‹‹85››. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9): 638–58.

‹‹86››. Manner H, Plum N, Pech O, Ell C, Enderle MD. Colon explosion during argon plasma coagulation. Gastrointest Endosc. 2008;67(7):1123–7.

‹‹87››. Ko CW, Dominitz JA. Complications of colonoscopy: magnitude and management. Gastrointest Endosc Clin N Am. 2010;20(4):659–71.

‹‹88››. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Ser vices Task Force. Ann Intern Med. 2008; 149(9):638–58.

‹‹89››. van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med. 2014;160(11):750–9.

‹‹90››. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9):638–58.

‹‹91››. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348:g2467.

‹‹92››. Swan H, Siddiqui AA, Myers RE. International colorectal cancer screening programs: population contact strategies, testing methods and screening rates. Pract Gastroenter. 2012;36(8): 20–9.

‹‹93››. Ling BS, Trauth JM, Fine MJ, et al. Informed decision-making and colorectal cancer screening: is it occurring in primary care? Med Care. 2008;46(9 Suppl 1):S23–9.

‹‹94››. Ling BS, Trauth JM, Fine MJ, et al. Informed decision-making and colorectal cancer screening: is it occurring in primary care? Med Care. 2008;46(9 Suppl 1):S23–9.

‹‹95››. Brett AS. Flexible sigmoidoscopy for colorectal cancer screening: more evidence, persistent ironies. JAMA. 2014;312(6):601–2.

‹‹96››. Yabroff KR, Klabunde CN, Yuan G, et al. Are physicians’ recommendations for colorectal cancer screening guideline-consistent? J Gen Intern Med. 2011;26(2):177–84.

‹‹97››. Swan H, Siddiqui AA, Myers RE. International colorectal cancer screening programs: population contact strategies, testing methods and screening rates. Pract Gastroenter. 2012;36(8):20–9.

‹‹98››. Swan H, Siddiqui AA, Myers RE. International colorectal cancer screening programs: population contact strategies, testing methods and screening rates. Pract Gastroenter. 2012;36(8): 20–9.

‹‹99››. Butterfi eld S. Changes coming for colon cancer screening. ACP Internist. 2014;34(7):10–11.

‹‹100››. Rosenthal E. The $2.7 trillion medical bill: colonoscopies explain why U.S. leads the world in health expenditures. New York Times. http://www.nytimes.com/2013/06/02/health/colonoscopies-explain-why-us-leads-the-world-in-health-expenditures.html. June 1, 2013. Accessed March 12, 2015.

‹‹101››. Whoriskey P, Keating D. How a secretive panel uses data that distorts doctors’ pay. Washington Post. http://www.washingtonpost.com/business/economy/how-a-secretive-panel-uses-data-that-distorts-doctors-pay/2013/07/20/ee134e3a-eda8-11e2-9008-61e94a7ea20d_story.html. July 20, 2013. Accessed March 12, 2015.

‹‹102››. US Government Accountability Office. Medicare: action needed to address higher use of anatomic pathology ser vices by providers who self-refer. GAO-13-445. http://www.gao.gov/products/GAO-13-445. June 24, 2013. Accessed March 12, 2015.

‹‹103››. Spirling LI, Daniels IR. Botanical perspectives on health peppermint: more than just an afterdinner mint. J R Soc Promot Health. 2001;121(1):62–3.

‹‹104››. Amato A, Liotta R, Mul? F. Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action. Eur J Pharmacol. 2014;740:295–301.

‹‹105››. Leicester RJ, Hunt RH. Peppermint oil to reduce colonic spasm during endoscopy. Lancet. 1982;2(8305):989.

‹‹106››. Asao T, Mochiki E, Suzuki H, et al. An easy method for the intraluminal administration of peppermint oil before colonoscopy and its effectiveness in reducing colonic spasm. Gastrointest Endosc. 2001;53(2):172–7.

‹‹107››. Shavakhi A, Ardestani SK, Taki M, Goli M, Keshteli AH. Premedication with peppermint oil capsules in colonoscopy: a double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg. 2012;75(3):349–53.

‹‹108››. Stange KC. Barbara Starfield: passage of the pathfinder of primary care. Ann Fam Med. 2011;9(4):292–6.

‹‹109››. Starfi eld B. Is US health really the best in the world? JAMA. 2000;284(4):483–5.

‹‹110››. Rappoport J. An exclusive interview with Dr. Barbara Starfield: medically caused death in America. Jon Rappoport’s Blog. https://jonrappoport.wordpress.com/2009/12/09/an-exclusive-interview-with-dr-barbara-starfield-medically-caused-death-in-america/. December 9, 2009. Accessed March 12, 2015.

‹‹111››. Millenson ML. The silence. Health Aff (Millwood). 2003;22(2):103–12.

‹‹112››. Holtzman NA. Chronicle of an unforetold death. Arch Intern Med. 2012;172(15):1174–7.

‹‹113››. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29(7):932–40.

Похожие книги из библиотеки